#IMS2025 hashtag - Bluesky

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma | OncLive Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

5 months ago

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS25 #IMS2025 #mmsm #oncology www.onclive.com/view/teclist...

0 0 0 0

Hematology Advisor

@hematologyadvisor.bsky.social

5 months ago

Teclistamab-Based Induction Regimens Produce “Very High” MRD Negativity Rates Teclistamab-based induction regimens have demonstrated efficacy in a phase 2 trial of patients with newly diagnosed multiple myeloma.

Teclistamab-based induction regimens have demonstrated efficacy in patients with newly diagnosed #multipleMyeloma. Presented at #IMS2025, covered by @cancertherapyadv.bsky.social.

https://bit.ly/438ADSX

0 0 0 0

Cancer Therapy Advisor

@cancertherapyadv.bsky.social

6 months ago

Findings from the phase 2 ISASOCUT study support the use of subcutaneous isatuximab plus VRd as a new standard of care in newly diagnosed MM, said Dr Arthur Bobin of @chu-poitiers.bsky.social, who presented these results at #IMS25. #IMS2025 #mmsm shorturl.at/iSblj

1 0 0 0

Cancer Therapy Advisor

@cancertherapyadv.bsky.social

6 months ago

Dr Rahul Banerjee’s Top 6 Presentations From IMS 2025 Dr Rahul Banerjee shares his favorite presentations from IMS 2025 and explains why he finds them interesting.

Dr Rahul Banerjee (@rahulbanerjeemd.bsky.social) of @fredhutch.org shares his favorite presentations from #IMS25. shorturl.at/xaGmE #IMS2025 #mmsm

2 1 0 0

Cancer Therapy Advisor

@cancertherapyadv.bsky.social

6 months ago

Teclistamab-based induction regimens have demonstrated efficacy in patients with newly diagnosed multiple myeloma, according to phase 2 trial results presented by @raabms.bsky.social at #IMIS25. shorturl.at/EEQSh #mmsm #ims2025

1 1 0 0

Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition | OncLive OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

6 months ago

Miss anything at #IMS2025? See which myeloma presentations and data stood out most to experts at the meeting.

Sign up and read exclusive expert insights! #mmsm #oncology www.onclive.com/view/myeloma...

0 0 0 0

Hematology Advisor

@hematologyadvisor.bsky.social

6 months ago

Subcutaneous Isatuximab Effective Across All Lines of Therapy in RRMM Researchers determined subcutaneous isatuximab is an effective therapy for patients with RRMM across all lines of therapy.

Subcutaneous administration of isatuximab using an OBI demonstrated similar response rates as the IV formulation regardless of the LOT among patients with R/R #multipleMyeloma. Presented at #IMS2025.

https://bit.ly/46PsR2D

1 0 0 0

Quadruplet Promising in Older Patients With Transplant-Ineligible Multiple Myeloma Favorable outcomes with modified daratumumab-based combo in newly diagnosed disease

6 months ago

A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data. #IMS2025
https://www.medpagetoday.com/meetingcoverage/ims/117573

1 0 0 0

Linvoseltamab Promising in High-Risk Smoldering Multiple Myeloma Bispecific antibody yields 100% overall response rate in early data from phase II trial

6 months ago

Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. #IMS2025
https://www.medpagetoday.com/meetingcoverage/ims/117570

1 0 0 0

Delaying Myeloma Progression Highly Valued by Patients, Physicians However, their reasons for this differ, survey shows

6 months ago

For some patients with multiple myeloma and their physicians, progression-free survival (PFS) is just as important as overall survival (OS), according to results from a cross-sectional survey. #IMS2025
https://www.medpagetoday.com/meetingcoverage/ims/117546

0 0 0 0

No Downsides to Achieving MRD Negativity in Myeloma Data will 'reassure physicians' that safety and quality of life won't be negatively affected

6 months ago

Achieving MRD negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed multiple myeloma, according to data from two phase III trials. #IMS2025
https://www.medpagetoday.com/meetingcoverage/ims/117559

3 0 0 0

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma | OncLive Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.

6 months ago

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/belanta...

1 0 0 0

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma | OncLive Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.

6 months ago

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/atlas-a...

1 0 0 0

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma | OncLive The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

6 months ago

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/stretch...

1 0 0 0

Society of Hematologic Oncology

@societyofhemonc.bsky.social

6 months ago

#IMS25 #IMS2025

0 0 0 0

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma | OncLive Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

6 months ago

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma @myeloma-society.bsky.social #IMS2025 #mmsm #oncology
www.onclive.com/view/eque-ce...

1 0 0 0

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma | OncLive D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

6 months ago

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS2025 #mmsm #oncology
hubs.li/Q03K79Td0

2 0 0 0

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma | OncLive OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

6 months ago

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/mainten...

2 0 0 0

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma | OncLive Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

6 months ago

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma @myeloma-society.bsky.social #IMS2025 #melsm
www.onclive.com/view/isa-krd...

1 0 0 0

IMS Annual Meeting - Day 1 - MMRF This week, the International Myeloma Society (IMS) is hosting its 22nd Annual Meeting—the world’s largest gathering of multiple myeloma researchers and clinicians. The MMRF team is on the ground in To...

6 months ago

Day 1 at #IMS2025 is in the books!

The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:

👉 themmrf.org/mmrf-blogs/i...

2 0 0 0

Society of Hematologic Oncology

@societyofhemonc.bsky.social

6 months ago

Daratumumab raises early infection risk in myeloma Daratumumab raises early infection risk in myeloma, accordiing to an oral abstract presented at IMS in Toronto.

Daratumumab raises early infection risk in myeloma
sohoinsider.com/multiple-mye...
#IMS25 #IMS2025

1 0 0 0

6 months ago

Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.

2 0 0 0

6 months ago

Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025

0 0 0 0